Synlogic (SYBX) Reports Q3 Loss of $0.43, Revenues Beat
Get Alerts SYBX Hot Sheet
Join SI Premium – FREE
Synlogic (NASDAQ: SYBX) reported Q3 EPS of ($0.43), versus $0.00 reported last year. Revenue for the quarter came in at $1.8 million versus the consensus estimate of $200 thousand.
“This is an exciting time for Synlogic, as we continue to explore the breadth of our platform. We have advanced SYNB1891, our dual innate immune activator for the treatment of cancer into IND-enabling studies,” said Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer. “Our two orally administered Synthetic Biotic medicines, SYNB1618 for the treatment of phenylketonuria and SYNB1020 for the treatment of hyperammonemia, have demonstrated proof of mechanism in healthy volunteers and we look forward to clinical data from the ongoing clinical trials in patients in 2019.”
For earnings history and earnings-related data on Synlogic (SYBX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- The Hartford (HIG) Misses Q1 EPS by 13c
- Juniper Networks (JNPR) Misses Q1 EPS by 12c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!